Growth axis
Growth-hormone signaling, secretagogues, hypothalamic factors, and related analogues.
Questions
What does the Growth axis category cover?
The sampled monographs include recombinant IGF-1 medicine mecasermin, the Japanese diagnostic pralmorelin, and investigational or unapproved secretagogues and analogues such as ipamorelin, CJC-1295, and AOD-9604. Their category placement reflects growth-axis biology, not interchangeability.
Which sampled Growth axis entries have a documented approval?
Mecasermin is approved in the United States, EU, and Canada for severe primary IGF-1 deficiency in children. GHRP-2, or pralmorelin, has a diagnostic approval in Japan. The sampled monographs identify no approved therapeutic product for ipamorelin, CJC-1295, or AOD-9604.
What human evidence separates mecasermin from ipamorelin?
Mecasermin's approval was supported by open-label studies reporting increased growth velocity in children with severe primary IGF-1 deficiency. Ipamorelin's only published phase 2 trial, in postoperative ileus, failed its primary endpoint. Those findings address different substances and indications and cannot be generalized across the category.
What does the CJC-1295 evidence establish?
The cited controlled studies establish pharmacokinetic and endocrine biomarker effects in healthy adults, not therapeutic efficacy. No approved CJC-1295 product was identified, and commercial naming can conflate the DAC-conjugated substance with a distinct non-DAC backbone. No established or recommended human dose exists.
Why does the AOD-9604 record matter when reading this category?
AOD-9604 illustrates why biological rationale is not enough: its obesity development program did not establish efficacy and no approved medicine was identified. The atlas methodology deliberately retains decisive negative evidence so that visibility in research markets is not mistaken for clinical validation.
Join the atlas. Get the evidence updates.
Receive concise notes when peptide evidence, status, or source records change.